1. Introduction {#sec1-medicina-55-00236}
===============

An epitope is a portion of an antigenic protein molecule that can be identified by the immune system of the human body by either B or T lymphocyte cells. The peptides can be interacted with through the T-cell receptors of the immune system. After being bound to at least one Major Histocompatibility Complex (MHC) protein, the antigenic proteins are intracellularly processed and exposed on the surface of the antigen presenting cell, known as the MHC-peptide complex. Since T lymphocytes play an active role in this type of immune response along with the specific MHC molecule from the antigen presenting cell for antigen presentation, this type of epitopes is therefore called a T-cell epitope \[[@B1-medicina-55-00236]\]. MHC molecules are cell surface glycoproteins, which actively contribute to host immune reactions. These MHC molecules are expressed from human HLA (Human Leukocyte Antigens) gene to participate in adaptive immune system in humans \[[@B2-medicina-55-00236]\].

The immunogenicity of T cell epitope is dependent on various factors e.g., suitable and actual peptide processing from its protein source, stable small peptide binding with the MHC molecule and lastly, recognition of the MHC-bound peptide molecule by the T cell receptor \[[@B3-medicina-55-00236]\]. Two types of MHC molecules known as MHC class I molecules normally present peptides containing 8 to 11 amino acids in length, but the peptides binding to MHC class II may have peptide lengths that vary from 12 to 25 amino acids \[[@B4-medicina-55-00236]\]. MHC class II protein molecules bind with fragments of the oligopeptide, obtained from the proteolytic cleavage of antigenic protein and present them on the cell surface of antigen presenting cells (APCs), to be recognized by CD4+ T cells. When adequate amounts of the epitope are presented, the T cell may generate a specific adaptive immune response for that pathogen through the process of positive selection. Class II MHC molecules are secreted on specialized cells, e.g., professional APCs such as B cells, macrophages and dendritic cells, whereas class I MHCs are expressed on every nucleated cell of the human body \[[@B5-medicina-55-00236]\].

In an ideal peptide-based vaccine, both B- and T-cell epitopes are present \[[@B2-medicina-55-00236]\]. B cell and T cell epitopes are recognized by two different pathways. The three-dimensional conformation of the antigenic protein molecule is wholly responsible for recognition by B cells, whereas T cells can recognize an antigen protein molecule only after it has been digested to form a small peptide fragment which must be bound with the major histocompatibility complex (MHC) class II molecule, forming a ternary complex.

Allergic symptoms are one of the most common health problems in the world. Among the four types of hypersensitivity reactions, more than 25% of the world's population suffers from a type I hypersensitivity reaction. Considering the various causes of allergic reactions, pollen allergens are predicted to be the most potential source of hypersensitivity reaction. Pollinosis due to various pollens results in allergic rhinitis and asthma \[[@B6-medicina-55-00236]\]. Grass pollen allergens from *Cynedondactylon*, *Orzya sativa*, *Zea mays* etc. are accountable for the allergic reaction in susceptible individuals in different parts of the world \[[@B7-medicina-55-00236]\]. Allergic diseases can be successfully treated by identifying clinically important allergens. Worldwide, about 400 million people are suffering from hay fever as well as seasonal asthma \[[@B8-medicina-55-00236]\]. The major causative biomolecules for this allergy are pollen proteins also known as the group-1 grass pollen allergens \[[@B9-medicina-55-00236]\]. Zea m 1 is found in a class of abundant grass pollen allergens, which are formed by several genes. These proteins can loosen the walls of grass cells, including the maize stigma and style \[[@B10-medicina-55-00236]\]. In a study, performed in Portugal on thirty-two children that are under 8 years of age, all are given a positive skin-prick test for grass pollen allergens \[[@B11-medicina-55-00236]\]. 38% of the children are monosensitized to different grass pollen allergens. The decreasing order of sensitization frequency for that pollens are shown in [Table 1](#medicina-55-00236-t001){ref-type="table"}.

To prevent the type I hypersensitivity reaction, drugs known as mast cell stabilizers e.g., synthetic, semi synthetic and natural stabilizers, can be used as therapeutic agents. These mast cell stabilizers obtained from natural resources can be classified into different groups such as flavonoids, coumarins, phenols \[[@B12-medicina-55-00236]\], terpenoids, alkaloids etc. Considering their mechanisms of action, mast cell stabilizers can be classified as Ca^2+^channel blocking agents, suppressors of gene expression of genes (tumor necrosis factor alpha, different interleukins), inhibitors for phosphorylation reactions in MAPK, ERK, JNK Gab2 signaling pathways, down regulators of enzyme histidine dicarboxylase, suppressors of mRNA of CD23, inhibitors of COX2/5 lipooxygenase enzyme, inhibitors of prostaglandin D~2~ synthesis, LTC~4~ inhibitors, and Spleen tyrosin kinase enzyme inhibitors \[[@B13-medicina-55-00236]\]. Explorations for alternative types of therapeutics in allergic reactions are explained in my earlier work where, a specific sense siRNA is explored as anti-allergic therapeutic during an immediate type of hypersensitivity reaction, caused by the Zea m 1 pollen allergenic protein \[[@B14-medicina-55-00236]\]. Presently, in allergen-specific immunotherapy (AIT), the disease-causing allergens are used for a disease-modifying treatment of allergy. The molecular allergen characterization process is applied, to produce allergy vaccines with the recombinant allergens, peptides and genes synthesizing allergens. The B-cell epitope technique is also another promising method used to identify the antigenic determinants or epitopes present in the antigenic proteins \[[@B15-medicina-55-00236]\]. Epitope based vaccine design is a state-of-art method, because it is very specific, is able to evade undesirable immune reactions, has the power to create long lasting immunity, and at the same time, it is cheap in price. This method has been applied to treat various diseases like tuberculosis \[[@B1-medicina-55-00236]\], Nipah virus infection \[[@B16-medicina-55-00236]\] etc. In this study, an epitope-based peptide vaccine design method is studied for Zea m 1 pollen allergen, with various T cell epitope prediction methods, followed by molecular docking technique. Prediction methods and docking experiments are performed to design peptide-based vaccines for an allergic reaction caused by Zea m 1 pollen allergen.

2. Materials and Methods {#sec2-medicina-55-00236}
========================

Different steps and computational methods applied to forecast T cell epitopes for preparing peptide-based vaccine for Zea m 1 pollen allergen areshown in [Figure A1](#medicina-55-00236-f0A1){ref-type="fig"}.

2.1. Retrieval of Zea m1 Pollen Allergen Protein in FASTA Format {#sec2dot1-medicina-55-00236}
----------------------------------------------------------------

The amino acid sequence and three-dimensional structure of Zea m 1 allergenic protein (PDB ID 2HCZ) are obtained from UniProt knowledgebase \[[@B17-medicina-55-00236]\].

2.2. MHC II Binding Epitope Prediction for Allergenic Protein {#sec2dot2-medicina-55-00236}
-------------------------------------------------------------

The MHC binding epitope prediction methods for Zea m 1 allergen can be classified into three groups such as (i) methods based on protein motifs, (ii) expression-based methods using statistics or mathematics and, (iii) methods based on structure of the allergen.

### 2.2.1. Motif Based Methods {#sec2dot2dot1-medicina-55-00236}

SYFPEITHIA DATABASE OF MHC LIGANDS AND PEPTIDE MOTIFS (Ver. 1.0) (<http://www.syfpeithi.de/>), is a database which comprises more than 7000 peptide sequences, known to bind class I and class II MHC molecules. Using FASTA sequence of Zea m 1 pollen allergen, epitopes for MHC II binding are searched.

### 2.2.2. Statistical/Mathematical Expression-Based Methods {#sec2dot2dot2-medicina-55-00236}

#### IEDB Recommended Method

The IEDB recommended method ([www.iedb.org](www.iedb.org)) is used to identify a T cell epitope, in which the Consensus approach, in combination with NN-align, SMM-align, CombLib and Sturniolo algorithms are applied. Here a NetMHCIIpan method is also used.

#### A Proteochemometrics Based Method

EpiTOP, a proteochemometrics based model theoretically predicts peptide binding to a whole group of MHC proteins (<http://www.pharmfac.net/EpiTOP>). This method helps to detect T cell epitopes on the basis of mathematical expression.

#### Specificity-Determining Residue (SDR) Concept

PREDIVAC, a method based \[[@B18-medicina-55-00236]\] on the specificity-determining residue (SDR) concept which covers 95% of MHC class II allelic variants. SDRs consist of a trivial set of structurally conserved locations in the peptide-binding interaction interface that are responsible for specific recognition of MHC II molecules. Peptide binding prediction to the HLA class II protein DRB3\*0101 is executed by parsing the query protein sequence into overlapping nonameric segments (peptides), each of which is assigned a Predivac binding score (0--100).

#### A Method is based on the QM (Quantitative Matrices) Approach

ProPred, a method is grounded on the QM (quantitative matrices) approach. It predicts binders for MHC class II molecules (<http://www.imtech.res.in/raghava/propred/>). This matrices-based method is also applied.

#### A MethodApplying Position Specific Scoring Matrices (PSSMs)

RANKPEP, a method (<http://imed.med.ucm.es/Tools/rankpep.html>) which forecasts peptide binders with the MHCII molecules from protein amino acid sequence/s or sequence alignments using Position Specific Scoring Matrices (PSSMs). Using this tool, MHC II binding epitopes of Zea m 1 are identified.

### 2.2.3. Structure Based Prediction Method {#sec2dot2dot3-medicina-55-00236}

Structure based methods are based on the molecular docking technique. These methods compute binding energy between peptide and MHC molecule and the energetically favorable peptides are predicted as binders. A flowchart for molecular docking procedure is shown in [Figure A2](#medicina-55-00236-f0A2){ref-type="fig"}.

2.3. Population Coverage Prediction of Putative Epitopes {#sec2dot3-medicina-55-00236}
--------------------------------------------------------

The following putative epitopes and their cumulative predicted coverage are calculated specifically for the set of HLA class II allelic variants occurring in the target population of Asia, according to allele frequency data recovered from the Allele Frequency Net Database (<http://www.allelefrequencies.net/>) \[[@B19-medicina-55-00236]\].

2.4. Analysis for the Effectiveness of Peptide-Based Vaccine in Other Group 1 Grass Pollen Allergens {#sec2dot4-medicina-55-00236}
----------------------------------------------------------------------------------------------------

To prove the effectiveness of these two peptides as the vaccines for whole group 1 grass pollen allergens, a search is performed to identify homologous allergens in the SDAP allergens database \[[@B20-medicina-55-00236]\]. SDAP (Structural Database of Allergenic Proteins) is a web server \[[@B20-medicina-55-00236]\] that delivers quick access to the peptide sequences, three-dimensional structures and IgE epitopes of allergenic proteins. The database component of SDAP comprises information about the name, source, sequence, structure, IgE epitopes and literature references for allergens and easy links to the major protein from various web browsers, such as-PDB, SWISS-PROT/TrEMBL, PIR-ALN, NCBI Taxonomy Browser, as well as from literature e.g., PubMed, MEDLINE.

3. Results {#sec3-medicina-55-00236}
==========

3.1. Retrieved Sequence of Zea m1 Pollen Allergen Protein in FASTA Format {#sec3dot1-medicina-55-00236}
-------------------------------------------------------------------------

An X ray crystallographic structure of Zea m 1 (PDB ID 2HCZ) is shown in [Figure 1](#medicina-55-00236-f001){ref-type="fig"} \[[@B17-medicina-55-00236]\]. This allergenic protein structure is used to identify a predicted T cell epitope for peptide mapping to design a vaccine.

3.2. T Cell Epitope Prediction for MHC II Binding {#sec3dot2-medicina-55-00236}
-------------------------------------------------

### 3.2.1. Epitope Search Results for Motif-Based Methods {#sec3dot2dot1-medicina-55-00236}

Result from SYFPEITHI, a DATABASE OF MHC LIGANDS AND PEPTIDE MOTIFS (Version 1.0), for prediction of CD4+ T cell epitope is shown in [Table 2](#medicina-55-00236-t002){ref-type="table"}.

The peptides VKVKYVADDGDIVLM and LSWGAIWRMDTAKAL are identified as predicted T cell epitopes for this antigenic protein from SYFPEITHI database and their prediction scores for various MHC II allelic proteins are shown in [Table 2](#medicina-55-00236-t002){ref-type="table"}.

### 3.2.2. Predicted T Cell Epitopes by Using Statistical/Mathematical Expression-Based Methods {#sec3dot2dot2-medicina-55-00236}

#### Results from IEDB Recommendation Method

The prediction method recommended by IEDB for MHC-II binding with CD4+ T cell epitope propose that the lower the percentile rank is for the epitope, the better it would be as a binder of the MHC II molecule. The predicted percentile rank using consensus and NetMHCIIpan methods for predicted T cell epitopes are shown in [Table 3](#medicina-55-00236-t003){ref-type="table"}.

#### Results from the EpiTOP 1.0 Method

The binding affinity of predicted T cell epitopes with MHC II molecules are expressed here as IC~50~ values ([Table 4](#medicina-55-00236-t004){ref-type="table"}).

#### Peptide Binding Prediction to the HLA Class II Protein DRB3\*01:01 Using PredivacMethod

From the IEDB recommendation method, MHC II allele HLA-DRB3\*01:01 is isolated as the most efficient MHC molecule for T cell binding with the lowest percentile rank ([Table 3](#medicina-55-00236-t003){ref-type="table"}). So, this allelic protein is used for the Predivac method to predict the nanomers as T cell epitopes with predicted scores ([Table 5](#medicina-55-00236-t005){ref-type="table"}).

#### Results for T Cell Epitope Prediction Using PROPRED Method

Predicted peptides along with their positions and predicted score in pollen allergen protein are displayed in [Table 6](#medicina-55-00236-t006){ref-type="table"} by using the PROPRED method.

#### Results from the RANKPEP Method

Predicted peptide sequences along with their positions and predicted score in pollen allergen protein, Zea m 1 are displayed in [Table 7](#medicina-55-00236-t007){ref-type="table"} by using the RANKPEP method.

### 3.2.3. Structure Based T Cell Epitope Prediction by Using Molecular Docking Technique {#sec3dot2dot3-medicina-55-00236}

From the above-mentioned methods two peptide sequences e.g. WRMDTAKAL and YVADDGDIV are selected as suitable T cell epitopes for the Zea m 1 allergenic protein. Similarly, a MHC II allele HLA-DRB3\*01:01 protein is detected as the most probable interacting MHC molecule. For docking studies, both T cell epitopes are nominated and subjected to predict three-dimensional structures using a PEP-FOLD server \[[@B21-medicina-55-00236],[@B22-medicina-55-00236]\] ([Figure 2](#medicina-55-00236-f002){ref-type="fig"}). The molecular interactions with specific HLA protein for respective epitopes are identified in docking studies with a ClusPro 2.2 web server \[[@B23-medicina-55-00236]\].

Molecular docking complexes for two predicted peptide structures with MHC II allele HLA-DRB3\*01:01 protein are shown in [Figure 3](#medicina-55-00236-f003){ref-type="fig"}. The estimated accuracy of docked structure for peptide YVADDGDIV is higher than that of WRMDTAKAL, as shown in [Table 8](#medicina-55-00236-t008){ref-type="table"}.

3.3. Population Coverage Prediction for Putative Epitopes {#sec3dot3-medicina-55-00236}
---------------------------------------------------------

The following putative epitopes and their cumulative predicted coverage are calculated specifically for the cluster of HLA class II gene allelic variants present in the Asian population. Population coverage prediction is estimated considering the allelic frequency data recovered from the Allele Frequency Net Database ([Table 9](#medicina-55-00236-t009){ref-type="table"}).

The prediction is carried out by considering 225 HLA class II proteins expressed in the target population.

3.4. Analysis for the Effectiveness of Peptide-Based Vaccine in Other Group 1 Grass Pollen Allergens {#sec3dot4-medicina-55-00236}
----------------------------------------------------------------------------------------------------

To prove the effectiveness of these two peptides as the vaccines for whole group 1 grass pollen allergens, a search is performed to identify homologous allergens, in the SDAP allergens database \[[@B20-medicina-55-00236]\]. A list of allergens, using the FASTA alignments among the Zea m 1 sequence and all SDAP allergens having an E score value higher than 0.010000 are shown in [Table 10](#medicina-55-00236-t010){ref-type="table"}.

Among these 50 allergens, 14 grass allergens are selected, omitting isoallergenic proteins. The multiple alignment sequence study for these two T cell epitopes such as YVADDGDIV and WRMDTAKAL in 14 grass allergens, is shown in [Figure 4](#medicina-55-00236-f004){ref-type="fig"}. This study shows that the locations of amino acids present in these epitopes are almost conserved, so these two epitopes may be effective for all these 14 grass allergens after clinical verification.

4. Discussion {#sec4-medicina-55-00236}
=============

Allergens cause type I hypersensitivity reactions mediated by immunoglobulin E (IgE) molecule. IgE biosynthesis, also known as sensitization, may be caused by airborne allergens, food allergens, drug allergens and occupational allergens. Modern clinical therapeutics for allergic reactions includes a combination of patient awareness, allergenic molecule avoidance, pharmacotherapy, and allergy immunotherapy. Allergy immunotherapy is a type of treatment targeting the basic immunological molecules and immunological pathways involved in allergic reaction and resulting in the activation of immunological tolerance by reducing IgE molecule reactivity and retaining T cell molecule reactivity \[[@B24-medicina-55-00236]\].A vast array of structurally altered allergens has been created, including allergenic oligopeptides, chemically modified allergoids, adjuvant-bound allergens, and nanoparticle-based allergy vaccines. In allergen-specific immunotherapy (AIT), repeated doses of sensitive allergens are used for desensitization or hypo-sensitization of allergic patients. Several herbal and natural products are reported to regulate antigen-IgE mediated allergic responses \[[@B25-medicina-55-00236],[@B26-medicina-55-00236]\]. There are other types of immunotherapeutic strategies that have also reported which use idiotype and anti-idiotype antibody interaction in vaccine production \[[@B27-medicina-55-00236]\] and epitope-paratope peptide modulation \[[@B28-medicina-55-00236],[@B29-medicina-55-00236]\]. Different bioinformatic algorithms, as well as computational methods \[[@B30-medicina-55-00236]\] are used for identifying biological functions of peptides.

Epitope-based vaccines are short oligopeptides derived from antigen that are used after antigen presentation to T-cells to prevent diseases like type I hypersensitivity. During antigen presentation, epitopes are bound with major histocompatibility complex (MHC) protein molecules. Peptide vaccines based on multiple T-cell epitopes can be administered for the rational use of immunogens among distinct ethnic populations, while providing numerous potential advantages over conventional vaccines. The advantages are more accurate regulation of the immune response activation, concentrating on most appropriate antigenic regions of a group of proteins (which are conserved and immunodominant in nature), as well as having advantages for production and biosafety. CD4+ T-cell epitopes display an important role in epitope-based vaccine design. The help of these cells is indispensable for the production of strong humoral and cytotoxic CD8+ T-cell responses. But the immune response to T-cell epitopes is limited only by HLA proteins. As a result, the HLA selectivity for T-cell epitopes develops a major constraint for epitope-based vaccine design, for genetically varied human populations. Two important factors cause major problems in epitope-based vaccine design. The most common problem is that MHC class II alleles are synthesized in different amounts in different ethnicities such as Asian and European populations. The second problem is that MHC class II genes are the most polymorphic genes in nature found in the human genome. Since the experimental testing of large sets of peptides of MHC molecules is very time-consuming as well as costly, in silico methods are more sought after methods to overcome these problems. Criteria-based analysis predicts two epitopes on this pollen allergen: YVADDGDIV and WRMDTAKAL. The T cell epitopes identified in this study provide insight into a peptide-based vaccine for type I hypersensitivity reaction induced by the Zea m 1 pollen allergen.

5. Conclusions {#sec5-medicina-55-00236}
==============

The crucial part of epitope-based vaccine design is its validation through in vivo and in vitro methods. Although two nonapeptides are identified by various motif based, statistical and structure-based methods, the experimental verification two epitopes YVADDGDIV and WRMDTAKAL is necessary to construct a vaccine against the Zea m 1 pollen allergen. This research work provides not only a novel pathway to design a peptide-based vaccine design for the Zea m1 pollen allergen, but at the same time the effectiveness of these two T cell epitopes is verified for 14 grass pollen allergens. Cross-reactivity occurs very frequently among these pollen allergen molecules due to very high sequence similarity in antigenic protein sequences. Almost conserved epitope sequences in these homologous proteins indicate the effectiveness of these predicted epitopes as probable vaccines for group 1 grass allergens. Population coverage calculation shows their efficiency in Asian populations. From a diagnostic point of view, these two T cell epitopes have immense importance for detecting the sensitivity of an individual towards the Zea m 1 pollen allergen. By preparing a monoclonal antibody with these two epitopes, diagnosis of a susceptible individual for hypersensitivity reaction in contact with a grass pollen allergen is possible. Allergen immune therapy with YVADDGDIV and WRMDTAKAL epitopes, will reduce immunogenic reactions in Zea m 1 sensitive populations.
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medicina-55-00236-t001_Table 1

###### 

Sensitization frequency of different grass pollen allergens

  No.    Sources of Grass Pollen Allergens   Sensitization Frequency
  ------ ----------------------------------- -------------------------
  1\.    *Dactylis*                          94%
  2\.    *Hordeum*                           75%
  3\.    *Phleum*                            72%
  4\.    *Poa*                               69%
  5\.    *Avena*                             66%
  6\.    *Festuca*                           63%
  7\.    *Triticum*                          59%
  8\.    *Secale*                            53%
  9\.    *Lolium*                            50%
  10\.   *Maize*                             31%

medicina-55-00236-t002_Table 2

###### 

Predicted epitopes from SYFPEITHI database

  Interacting MHC II Alleles          Predicted T Cell Epitopes       Prediction Score
  ----------------------------------- ------------------------------- ------------------
  HLA-DRB1\*0101 15---mers            V K V K Y V A D D G D I V L M   8
  HLA-DRB1\*0301 (DR17) 15---mers     V K V K Y V A D D G D I V L M   0
  HLA-DRB1\*0401 (DR4Dw4) 15---mers   V K V K Y V A D D G D I V L M   12
  HLA-DRB1\*0701 15---mers            V K V K Y V A D D G D I V L M   20
  HLA-DRB1\*1101 15---mers            V K V K Y V A D D G D I V L M   1
  HLA-DRB1\*1501 (DR2b) 15---mers     V K V K Y V A D D G D I V L M   4
  HLA-DRB1\*0101 15---mers            L S W G A I W R M D T A K A L   11
  HLA-DRB1\*0301 (DR17) 15---mers     L S W G A I W R M D T A K A L   0
  HLA-DRB1\*0401 (DR4Dw4) 15---mers   L S W G A I W R M D T A K A L   6
  HLA-DRB1\*0701 15---mers            L S W G A I W R M D T A K A L   4
  HLA-DRB1\*1101 15---mers            L S W G A I W R M D T A K A L   6
  HLA-DRB1\*1501 (DR2b) 15---mers     L S W G A I W R M D T A K A L   14

medicina-55-00236-t003_Table 3

###### 

T cell prediction results from IEDB recommendation method.

  Allele            Start   End   Peptide           Method Used                    Percentile Rank
  ----------------- ------- ----- ----------------- ------------------------------ -----------------
  HLA-DRB3\*01:01   216     230   LSWGAIWRMDTAKAL   Consensus (comb.lib./smm/nn)   0.01
  HLA-DRB3\*01:01   217     231   SWGAIWRMDTAKALK   Consensus                      0.01
  HLA-DRB3\*01:01   218     232   WGAIWRMDTAKALKG   Consensus                      0.01
  HLA-DRB3\*01:01   219     233   GAIWRMDTAKALKGP   Consensus                      0.01
  HLA-DRB3\*01:01   220     234   AIWRMDTAKALKGPF   Consensus                      0.01
  HLA-DRB3\*01:01   221     235   IWRMDTAKALKGPFS   Consensus                      0.01
  HLA-DRB3\*01:01   187     201   VLVKYVADDGDIVLM   Consensus                      0.12
  HLA-DRB3\*01:01   188     202   LVKYVADDGDIVLME   Consensus                      0.12
  HLA-DRB4\*01:01   194     208   DDGDIVLMEIQDKLS   Consensus                      0.14
  HLA-DRB4\*01:01   195     209   DGDIVLMEIQDKLSA   Consensus                      0.14
  HLA-DRB4\*01:01   196     210   GDIVLMEIQDKLSAE   Consensus                      0.14
  HLA-DRB3\*01:01   186     200   AVLVKYVADDGDIVL   Consensus                      0.15
  HLA-DRB4\*01:01   193     207   ADDGDIVLMEIQDKL   Consensus                      0.15
  HLA-DRB3\*02:02   218     232   WGAIWRMDTAKALKG   NetMHCIIpan                    0.15
  HLA-DRB1\*08:02   218     232   WGAIWRMDTAKALKG   Consensus (smm/nn/sturniolo)   0.17
  HLA-DRB4\*01:01   192     206   VADDGDIVLMEIQDK   Consensus                      0.18

medicina-55-00236-t004_Table 4

###### 

Predicted T cell epitopes from EpiTOP 1.0 tool.

  Position   Peptide     log (1/IC50)
  ---------- ----------- --------------
  189        VKYVADDGD   5.740
  188        LVKYVADDG   5.740
  187        VLVKYVADD   5.740
  185        LAVLVKYVA   5.740
  191        YVADDGDIV   5.740
  192        VADDGDIVL   5.740
  200        LMEIQDKLS   5.740
  199        VLMEIQDKL   5.740
  198        IVLMEIQDK   5.740
  184        YLAVLVKYV   5.740
  176        IEKGCNPNY   5.740
  159        FRRVRCKYP   5.740
  157        VEFRRVRCK   5.740
  155        MDVEFRRVR   5.740

medicina-55-00236-t005_Table 5

###### 

Predicted epitopes using the Predivac method

  ID   Nanomer     Score   Start   End
  ---- ----------- ------- ------- -----
  1    WRMDTAKAL   88.29   222     231
  2    VADDGDIVL   85.73   192     201
  3    YVADDGDIV   77.06   191     200
  4    YHFDLSGKA   73.82   128     137
  5    IAKDVIPAN   71.61   247     256
  6    MDTAKALKG   70.21   224     233
  7    IFKDGKGCG   67.41   87      96

medicina-55-00236-t006_Table 6

###### 

Predicted T cell epitopes by the PROPRED method

  Rank   Sequence    At Position   Score    \% of Highest Score
  ------ ----------- ------------- -------- ---------------------
  1      WRPDAVYTS   255           6.6500   73.08
  2      WRMDTAKAL   221           4.0000   43.96
  3      YHFDLSGKA   127           3.9000   42.86
  4      MVVGAVLAA   8             3.5000   38.46
  5      IFKDGKGCG   86            2.5000   27.47
  6      IRHCGIMDV   148           2.5000   27.47
  7      YVADDGDIV   190           2.4000   26.37
  8      IVLMEIQDK   197           2.4000   26.37
  9      VRCKEKPEC   99            2.2000   24.18
  10     MEIQDKLSA   200           2.1000   23.08
  11     WGAIWRMDT   217           1.9000   20.88

medicina-55-00236-t007_Table 7

###### 

Predicted results from the RANKPEP method.

  RANK   POS.   N     SEQUENCE    C     MW (Da)   SCORE    \% OPT.
  ------ ------ ----- ----------- ----- --------- -------- ---------
  1      222    GAI   WRMDTAKAL   KGP   1050.27   18.994   39.37%
  2      221    WGA   IWRMDTAKA   LKG   1050.27   17.006   35.25%
  3      50     RAT   WYGQPNGAG   APD   907.97    14.588   30.24%
  4      211    SAE   WKPMKLSWG   AIW   1068.36   12.582   26.08%
  5      256    PAN   WRPDAVYTS   NVQ   1053.18   12.238   25.37%
  6      15     GAV   LAALVAGGS   CGP   739.87    11.915   24.70%
  7      76     LPP   YSGMTACGN   VPI   884.97    11.738   24.33%
  8      191    LVK   YVADDGDIV   LME   948.0     11.246   23.31%
  9      122    DMN   YEPIAPYHF   DLS   1118.28   8.83     18.30%
  10     43     NGK   WLTARATWY   GQP   1103.31   8.514    17.65%

medicina-55-00236-t008_Table 8

###### 

Docking results for two predicted epitopes.

  Model   Protein Template   Peptide Template   Protein Structure Similarity (TM-Score)   Interaction Similarity Score   Estimated Accuracy
  ------- ------------------ ------------------ ----------------------------------------- ------------------------------ --------------------
  1       2Q6W_B             2Q6W_C             1.000                                     177.0                          1.000
  2       2Q6W_B             2Q6W_C             1.000                                     124.0                          0.904
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###### 

Predicted population coverage for predicted peptides.

  Peptide     Cumulative Coverage   Protein Localization   
  ----------- --------------------- ---------------------- -----
  IMVVGAVLA   60.17                 8                      16
  MTACGNVPI   74.55                 79                     87
  IPANWRPDA   91.42                 252                    260
  FGSLAKPGL   91.49                 137                    145
  YVADDGDIV   96.13                 191                    199
  MGSLANNIM   96.16                 1                      9
  IWRMDTAKA   96.40                 221                    229
  YHFDLSGKA   96.86                 128                    136
  FHIEKGCNP   96.87                 174                    182

medicina-55-00236-t010_Table 10

###### 

List of homologous allergens of Zea m1 in the SDAP allergen database.

  No   Allergen        Sequence Link in SwissProt/NCBI/PIR   Sequence Length   Bit Score   E Score
  ---- --------------- ------------------------------------- ----------------- ----------- ---------------
  1    Zea m 1         P58738                                269               342.2       9.0 × 10^−96^
  2    Pas n 1.0101    ACA23876                              265               294.2       2.4 × 10^−81^
  3    Ory s 1         AAF72990                              269               270.3       4.0 × 10^−74^
  4    Zea m 1         Q07154                                191               261.1       1.6 × 10^−71^
  5    Ory s 1         AAF72983                              267               237.9       2.2 × 10^−64^
  6    Ory s 1         AAF72991                              267               235.8       9.3 × 10^−64^
  7    Phl p 1         P43213                                263               223.7       4.3 × 10^−60^
  8    Phl p 1.0101    CAA81613                              263               223.3       5.6 × 10^−60^
  9    Cyn d 1         O04701                                246               221.7       1.6 × 10^−59^
  10   Hol l 1.0102    CAA93121                              248               220.5       3.5 × 10^−59^
  11   Hol l 1         P43216                                265               220.4       4.0 × 10^−59^
  12   Hol l 1         CAA10140                              263               218.9       1.2 × 10^−58^
  13   Cyn d 1         AAL14078                              262               217.4       3.3 × 10^−58^
  14   Cyn d 1.0203    AAL14079                              262               216.8       4.9 × 10^−58^
  15   Cyn d 1.0202    AAL14077                              262               216.8       4.9 × 10^−58^
  16   Poa p a         CAA10520                              263               216.4       6.4 × 10^−58^
  17   Pha a 1         Q41260                                269               216.3       7.4 × 10^−58^
  18   Cyn d 1.0204    AAF80379                              244               215.8       9.4 × 10^−58^
  19   Cyn d 1.0201    AAK96255                              244               214.8       1.8 × 10^−57^
  20   Lol p 1.0103    CAB63699                              263               214.9       1.8 × 10^−57^
  21   Ory s 1         AAF72987                              275               214.8       2.1 × 10^−57^
  22   Lol p 1.0102    AAA63278                              252               213.9       3.5 × 10^−57^
  23   Lol p 1.0101    AAA63279                              263               213.2       6.0 × 10^−57^
  24   Lol p 1         P14946                                263               212.8       7.9 × 10^−57^
  25   Ory s 1         AAF72984                              268               210.7       3.4 × 10^−56^
  26   Ory s 1         AAF72985                              286               207.8       2.8 × 10^−55^
  27   Tri a ps93      AAD10496                              271               205.0       1.8 × 10^−54^
  28   Ory s 1         AAB61710                              261               204.8       2.0 × 10^−54^
  29   Ory s 1         Q40638                                263               200.6       3.6 × 10^−53^
  30   Sor h 1.0101    ABC58726                              239               199.6       6.9 × 10^−53^
  31   Ory s 1         AAF72989                              271               197.4       3.4 × 10^−52^
  32   Ory s 1         AAF72988                              327               165.7       1.5 × 10^−42^
  33   Gly m 2         AAA50175                              277               154.8       2.3 × 10^−39^
  34   Ory s 1         AAF72986                              275               144.9       2.2 × 10^−36^
  35   Arat expansin   CAB37496                              265               90.5        5.3 × 10^−20^
  36   Ory s 1         AAG13596                              275               83.7        6.1 × 10^−18^
  37   Ory s 1         BAA85432                              284               81.4        3.0 × 10^−17^
  38   Cyn d 2         CAA10346                              122               53.4        3.5 × 10^−9^
  39   Dac g 2         CAA10345                              122               52.7        5.9 × 10^−9^
  40   Poa p 2         CAA10348                              122               52.7        5.9 × 10^−9^
  41   Phl p 2         P43214                                122               52.7        5.9 × 10^−9^
  42   Lol p 2         P14947                                97                48.8        7.0 × 10^−8^
  43   Dac g 3         P93124                                96                48.0        1.2 × 10^−7^
  44   Lol p 2         CAA51775                              88                46.4        3.3 × 10^−7^
  45   Phl p 3.0101    2JNZ_A                                108               44.5        1.5 × 10^−6^
  46   Dac g 1.0101    Q7M1X8                                34                42.4        2.0 × 10^−6^
  47   Lol p 3         P14948                                97                43.1        3.6 × 10^−6^
  48   Cyn d 15        AAP80171                              112               43.2        3.7 × 10^−6^
  49   Ant o 1.0101    Q7M1X6                                32                38.9        2.2 × 10^−5^
  50   Tri a 3         CAA90746                              118               39.7        4.6 × 10^−5^
